Top

Clinical and Translational Oncology

Published in:

01-10-2019 | NSCLC | Research Article

The detection and clinical significance of peripheral regulatory CD4⁺CD25^hiCD127^low T cells in patients with non-small cell lung cancer

Authors: J. Qiu, G. Che, F. Liu, X. Sha, S. Ju, H. Ma, L. Feng

Published in: Clinical and Translational Oncology | Issue 10/2019

Abstract

Objective

In this study, we aimed to discuss the clinical significance of CD4⁺CD25^hiCD127^low regulatory T cells (Tregs) in the peripheral blood of patients with non-small cell lung cancer (NSCLC).

Methods

Sixty patients with NSCLC and 35 healthy controls were studied. Peripheral blood CD4⁺CD25^hiCD127^lowTregs, CD4⁺CD25^hiT cells, and CD4⁺T cells were measured with flow cytometric analysis, and results were compared between the groups.

Results

Compared with healthy people, CD4⁺CD25^hiCD127^low Tregs and CD4⁺CD25^hi T cells significantly increased in patients with NSCLC, while CD4⁺ T cell proportions decreased.

Conclusions

CD4⁺CD25 ^hi CD127^low Treg detection in the peripheral blood of NSCLC patients is highly significant, in that it provides additional knowledge to guide the selection of individualized treatment plans for patients with NSCLC.

Zhou J, Min Z, Zhang D, Wang W, Marincola F, Wang X. Enhanced frequency and potential mechanism of B regulatory cells in patients with lung cancer. J Transl Med. 2014;12:304. https://doi.org/10.1186/s12967-014-0304-0.CrossRefPubMedPubMedCentral

Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Pillars article: immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995;186(7):3808–21 (Baltimore, Md: 1950. 2011).

Liu C, Workman CJ, Vignali DA. Targeting regulatory T cells in tumors. FEBS J. 2016;283(14):2731–48. https://doi.org/10.1111/febs.13656.CrossRefPubMed

Vignali DA, Collison LW, Workman CJ. How regulatory T cells work. Nat Rev Immunol. 2008;8(7):523–32. https://doi.org/10.1038/nri2343.CrossRefPubMedPubMedCentral

Baecher-Allan C, Viglietta V, Hafler DA. Human CD4 + CD25 + regulatory T cells. Semin Immunol. 2004;16(2):89–98. https://doi.org/10.1016/j.smim.2003.12.005.CrossRefPubMed

Chen Z, Ding J, Pang N, Du R, Meng W, Zhu Y, et al. The Th17/Treg balance and the expression of related cytokines in Uygur cervical cancer patients. Diagn Pathol. 2013;8:61. https://doi.org/10.1186/1746-1596-8-61.CrossRefPubMedPubMedCentral

Woo EY, Yeh H, Chu CS, Schlienger K, Carroll RG, Riley JL, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol (Baltimore, Md: 1950). 2002;168(9):4272–6.CrossRef

Islas-Vazquez L, Prado-Garcia H, Aguilar-Cazares D, Meneses-Flores M, Galicia-Velasco M, Romero-Garcia S, et al. LAP TGF-beta subset of CD4(+)CD25(+)CD127(-) treg cells is increased and overexpresses LAP TGF-beta in lung adenocarcinoma patients. Biomed Res Int. 2015;2015:430943. https://doi.org/10.1155/2015/430943.CrossRefPubMedPubMedCentral

Wang J, Yang J. Identification of CD4(+)CD25(+)CD127(-) regulatory T cells and CD14(+)HLA(-)DR(-)/low myeloid-derived suppressor cells and their roles in the prognosis of breast cancer. Biomed Rep. 2016;5(2):208–12. https://doi.org/10.3892/br.2016.694.CrossRefPubMedPubMedCentral

10.

Ellis GI, Reneer MC, Velez-Ortega AC, McCool A, Marti F. Generation of induced regulatory T cells from primary human naive and memory T cells. J Vis Exp. 2012. https://doi.org/10.3791/3738.CrossRefPubMedPubMedCentral

11.

Angin M, King M, Addo MM. New tools to expand regulatory T cells from HIV-1-infected individuals. J Vis Exp. 2013;75:e50244. https://doi.org/10.3791/50244.CrossRef

12.

Kono K, Kawaida H, Takahashi A, Sugai H, Mimura K, Miyagawa N, et al. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers. Cancer Immunol Immunother. 2006;55(9):1064–71. https://doi.org/10.1007/s00262-005-0092-8.CrossRefPubMed

13.

Peguillet I, Milder M, Louis D, Vincent-Salomon A, Dorval T, Piperno-Neumann S, et al. High numbers of differentiated effector CD4 T cells are found in patients with cancer and correlate with clinical response after neoadjuvant therapy of breast cancer. Can Res. 2014;74(8):2204–16. https://doi.org/10.1158/0008-5472.Can-13-2269.CrossRef

14.

Sharma S, Khosla R, David P, Rastogi A, Vyas A, Singh D, et al. CD4 + CD25 + CD127(low) regulatory T cells play predominant anti-tumor suppressive role in hepatitis B virus-associated hepatocellular carcinoma. Front Immunol. 2015;6:49. https://doi.org/10.3389/fimmu.2015.00049.CrossRefPubMedPubMedCentral

15.

Zhong A, Pan X, Shi M. Expression of PD-1 by CD4(+)CD25(+)CD127(low) Treg cells in the peripheral blood of lung cancer patients. OncoTargets Ther. 2015;8:1831–3. https://doi.org/10.2147/ott.S90538.CrossRef

16.

Rabe H, Nordstrom I, Andersson K, Lundell AC, Rudin A. Staphylococcus aureus convert neonatal conventional CD4(+) T cells into FOXP3(+) CD25(+) CD127(low) T cells via the PD-1/PD-L1 axis. Immunology. 2014;141(3):467–81. https://doi.org/10.1111/imm.12209.CrossRefPubMedPubMedCentral

Title: The detection and clinical significance of peripheral regulatory CD4+CD25hiCD127low T cells in patients with non-small cell lung cancer
Authors: J. Qiu
G. Che
F. Liu
X. Sha
S. Ju
H. Ma
L. Feng
Publication date: 01-10-2019
Publisher: Springer International Publishing
Keywords: NSCLC
NSCLC
Published in: Clinical and Translational Oncology / Issue 10/2019
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-019-02063-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Objective

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2019

Evidence mapping based on systematic reviews of therapeutic interventions for soft tissue sarcomas

Data from real world to evaluate the efficacy of osimertinib in non-small cell lung cancer patients with central nervous system metastasis

Recommendations for follow-up of colorectal cancer survivors

A comprehensive analysis of factors related to carmustine/bevacizumab response in recurrent glioblastoma

Multiple sclerosis outcomes after cancer immunotherapy

Correction to: Recommendations for follow‑up of colorectal cancer survivors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer